Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

Related Keywords

New York ,United States ,Philadelphia ,Pennsylvania ,Ciltacabtagene Autoleucel ,Mary Pat Lancelotta ,Daratumumab Krd Dara ,Lenalidomide Vi ,Obinutuzumab Clb ,Idecabtagene Vicleucel ,York State Clinical Laboratory Evaluation Program ,Exchange Commission ,Community Pathway ,Levine Cancer Institute ,Nitin Sood ,T Cell Engaging Bispecific Antibody ,Induces Durable Clinical ,Molecular Responses ,Refractory Multiple Myeloma ,Clinical High Risk Multiple Myeloma Patients ,Early Relapse ,Frontline Autologous Stem Cell Transplantation ,First In Human Phase ,Modakafusp Alfa ,Immune Targeting Attenuated Cytokine ,Multiple Myeloma ,Karmma Achieving Prolonged ,Guide Discontinuation ,Maintenance Therapy ,Disease Kinetics Among Patients ,High Risk Factors Treated ,Versus Chlorambucil Plus Obinutuzumab ,Glow Study ,Previously Untreated Patients ,High Risk Disease ,Subgroup Analysis ,Sensitive Next Generation Sequencing Establishes ,Prognostic Value ,Very Low ,Real Time Monitoring ,Mantle Cell Lymphoma ,Limited Ibrutinib ,Tisagenlecleucel Is Highly Effective ,Refractory Mantle Cell Lymphoma ,Including Those ,Btki Refractory Disease ,First Report ,Tarmac Study ,Refractory Follicular Lymphoma ,Minimal Residual Disease ,Watch Registry ,Real World Observational Study Using Clonoseq ,Lymphoid Malignancies ,High Throughput Sequencing ,Immunoglobulin Genes ,Lymphoid Malignancy ,Sequential Combination ,Ponatinib Followed By Blinatumomab ,Acute Lymphoblastic Leukemia ,Novel Subgroup Analyses ,Largeb Cell ,Plus Venetoclax ,Year Safety ,Efficacy Analysis ,Effective Surveillance Tool ,Real World Study ,Systemic Light Chain Amyloidosis ,Risk Adaptive Phase ,Newly Diagnosed Multiple Myeloma ,Autologous Transplantation ,Minimal Residual Disease Adapted Consolidation ,Treatment Cessation ,Older Adults ,Master Trial ,Adapted Treatment Modulation ,Extended Follow ,Once Weekly Carfilzomib ,Newly Diagnosed ,Transplant Eligible Multiple Myeloma ,Clinical High Risk Multiple Myeloma Due ,Inadequate Response ,Frontline Autologous Stem Cell ,Initial Therapy ,Quadruplet Therapy ,Measurable Residual Disease ,Informed Treatment Adaptation ,Academic Community Pathway ,Pilot Study Combining Single Cell Multiomics ,Immune Reconstitution Following Therapy ,Autologous Hematopoietic Cell Transplantation ,Response Adapted Treatment Cessation ,Plus Lenalidomide ,Maia Age Subgroup Analysis ,Versus Lenalidomide ,Transplant Ineligible Patients ,Plus Bortezomib ,Versus Bortezomib ,Updated Analysis ,New York State ,Clinical Laboratory Evaluation Program ,Adaptive Biotechnologie ,Financial Condition ,